Back HIV/AIDS

HIV / AIDS

IAS 2015: Treatment Cascades Show 90-90-90 Goals Reachable, Eastern Europe Lags Behind Africa

A global analysis of HIV treatment cascades -- the proportions of people diagnosed with HIV, in care, on treatment, and virally suppressed -- shows that some of the world’s richest countries still fall far short of achieving the UNAIDS 90-90-90 targets, research from Imperial College London shows. Progress is worst in Eastern Europe, where most countries lag behind average performance in sub-Saharan Africa on every indicator.

alt

 

IAS 2015: Test and Treat Studies and African Country Experience Show 90-90-90 Targets Are Achievable

Health services in some African countries including Botswana, Rwanda, and Malawi are now providing effective HIV treatment to a greater proportion of their HIV-positive citizens than the U.S. and other rich countries. Meanwhile, some of the first data to come from large African studies examining the population-level impact of treatment as prevention suggest that the objectives of testing and treating 90% of those eligible can be achieved.

alt

IAS 2015: Same-day Antiretroviral Treatment Leads to Faster HIV Suppression in San Francisco

A program at San Francisco General Hospital (SFGH) that offers antiretroviral therapy (ART) on the same day as HIV diagnosis led to a high rate of treatment uptake and more rapid viral load suppression than standard practices, according to late-breaking study findings presented at the 8th International AIDS Society Conference this week in Vancouver. Newly diagnosed people with HIV and clinic providers both expressed enthusiasm about the RAPID program, which is now being implemented more widely as part of the city's Getting to Zero initiative.

alt

IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones

People who switch from the current version of tenofovir (TDF) to tenofovir alafenamide (TAF) -- a new formulation that reaches higher levels in HIV-infected cells -- maintained undetectable viral load and saw improvements in liver function biomarkers and bone density, according to a pair of studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver.

alt

IAS 2015: Intermittent PrEP May Be Robust Strategy for Anal Sex -- Vaginal Protection Less Certain

The pharmacodynamics (drug absorption and elimination rates) of the 2 drugs that comprise Truvada may favor the efficacy of intermittent pre-exposure prophylaxis (PrEP) more than previously thought, at least when it comes to protection from transmission via anal sex, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

IAS 2015: Raltegravir Prevents Mother-to-Child HIV Transmission During Late Pregnancy

Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment of pregnant women with HIV -- and potentially their infants -- to prevent perinatal transmission, according to study findings presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver.

alt

IAS 2015: HIV Treatment as Prevention Works [VIDEO]

The dramatic decreases in HIV sexual transmission among heterosexual couples when the positive partner is on suppressive antiretroviral therapy seen in the landmark HPTN 052 trial were sustained over the course of the multi-year study, according to final trial data presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention this week in Vancouver.

alt